Identify and acquire businesses in the life sciences sector. Utilize various strategies including mergers, stock purchases, and reorganizations. Now — the numbers.
There is not enough trading history here to call this an established business.
Red columns mark years that ended in a loss.
If every debt were paid off today, $90.6M would still be left in the vault — a solid cushion for hard times.
The market pays 32× for every dollar this company earns in a year — a price that already assumes things go well.
No analyst target is on record for this company.
There is $96.6M in the vault; even if every debt were paid off, $90.6M would remain.
Since the drop from its peak, buyer appetite hasn’t come back.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: earnings execution, the revenue breakdown, the price history.